Impedimed Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Impedimed Ltd (IPD)
Track today's live Impedimed (IPD) share price, performance and key data on this page with our current Sydney:IPD stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Impedimed share price on the Sydney exchange. Use the dropdown to switch exchange for the IPD share price, head to our technical summary section, which provides analysis on Impedimed share price buy/sell indicators using real-time data (or discuss the Impedimed (IPD) stock price today with other investors in the Impedimed ASX share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current ASX:IPD share price (ISIN: AU000000IPD8) to enhance your trading decisions with our free investment tools and resources.
What Is the Impedimed Ltd Share Price Today?
The Impedimed share price today is 0.006.
What Is the Stock Symbol for Impedimed Ltd
The stock symbol (or 'ticker') for Impedimed Ltd is "IPD."
What Stock Exchange Does Impedimed Ltd Trade On?
Impedimed Ltd is listed and trades on the Sydney stock exchange.
Is Impedimed Ltd a Good Stock to Buy?
Determining whether Impedimed (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current ASX:IPD share price (ISIN: AU000000IPD8) to enhance your trading decisions with our free investment tools and resources.
What Is the Impedimed Ltd Share Price Today?
The Impedimed share price today is 0.006.
What Is the Stock Symbol for Impedimed Ltd
The stock symbol (or 'ticker') for Impedimed Ltd is "IPD."
What Stock Exchange Does Impedimed Ltd Trade On?
Impedimed Ltd is listed and trades on the Sydney stock exchange.
Is Impedimed Ltd a Good Stock to Buy?
Determining whether Impedimed (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Sydney
Currency in AUD
0.006
0.000(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.005
0.006
52 wk Range
0.003
0.055
IPD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0050.006
52 wk Range
0.0030.055
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
IPD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
0.021
Upside
+248.50%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Impedimed Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Impedimed Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Impedimed Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Impedimed Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 0.021
(+248.50% Upside)
Impedimed Ltd Earnings Call Summary for Q4/2026
- ImpediMed reported Q4 cash outflow of AUD 4.9M in line with expectations; record cash receipts of AUD 4.3M boosted by upfront customer payments.
- Company completed AUD 15.3M capital raise, reducing debt from AUD 16M to AUD 11.5M; implemented AUD 5M annualized cost cuts effective July 1.
- ARR reached AUD 14.4M with 4% constant-currency growth; unit sales rose to 40 devices from 30, though management deemed performance below targets.
- Stock unchanged at $0.004, down 92% year-over-year near 52-week lows; market cap stands at just $6.5M despite potential undervaluation signals.
- Management expects quarterly savings of AUD 1M-1.5M going forward; early Q1 sales tracking ahead with focus on cancer, heart failure, and body composition.
Last Updated: 28/07/2026, 00:44
Read Full TranscriptEarnings
Latest Release
27/08/2026
EPS / Forecast
-0.01 / --
Revenue / Forecast
7.1M / 4.4M
Compare IPD to Peers and Sector
Metrics to compare | IPD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −1.6x | −0.4x | |
PEG Ratio | 0.63 | −0.27 | 0.00 | |
Price/Book | 2.2x | 3.9x | 2.6x | |
Price / LTM Sales | 1.5x | 3.2x | 3.1x | |
Upside (Analyst Target) | 191.7% | 44.9% | 48.9% | |
Fair Value Upside | Unlock | 12.8% | 6.8% | Unlock |
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure. It also provides Lymphedema Prevention Program; and BodyComp Analysis for survivorship health. The company specializes in cancer survivorship, heart health management, medical weight management, wellness, and research. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Impedimed (Sydney: IPD) Share Price Today?
The Impedimed stock price today is 0.006 AUD.
What Stock Exchange Does Impedimed (IPD) Trade On?
Impedimed is listed and trades on the Sydney Stock Exchange.
What Is the Ticker (Stock Symbol) for Impedimed?
The stock symbol (also called a 'ticker') for Impedimed is "IPD."
What Is the Current Impedimed Market Capitalisation?
As of today, Impedimed (Sydney: IPD) market cap is 20.140M AUD.
What Is Impedimed's (IPD) Earnings Per Share (TTM)?
The Impedimed EPS is currently -0.012 (Trailing Twelve Months).
When Is the Next Impedimed Earnings Date?
Impedimed's next earnings report will be released on 29/10/2026.
Is IPD a Buy or Sell From a Technical Analyst Perspective?
Based on today's Impedimed moving averages and other technical indicators, the daily buy/sell signal for IPD stock is Buy.
How Many Times Has Impedimed Stock Split?
Impedimed has split 6 times. (See the IPD stock split history page for full effective split date and price information.)
How Many Employees Does Impedimed Have?
Impedimed has 66 employees, based on their latest Companies House report.
What is the current trading status of Impedimed (Sydney: IPD)?
As of 06/09/2026, Impedimed (IPD) is trading at a share price of 0.006 AUD, with a previous close of 0.005 AUD. The stock has fluctuated within a day range of 0.005 AUD to 0.006 AUD, while its 52-week range spans from 0.003 AUD to 0.055 AUD.
What Is Impedimed (IPD) Price Target According to Analysts?
The average 12-month price target for Impedimed is 0.021 AUD, with a high estimate of 0.04 AUD and a low estimate of 0.00863 AUD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +248.50% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.